Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) held its Annual General Meeting of Shareholders in Vancouver, British Columbia on December 30, 2022, with 23,664,112 shares, representing 9.39% of its issued and outstanding Common Shares, being represented by shareholders present in person and by proxy.
At the Meeting held on 30th of November, 2022, Sirona’s shareholders approved all matters put forward to them for consideration, including the election of the board of directors, the appointment of DeVisser Gray LLP as the Company’s auditor, and the confirmation and approval of the Company’s existing stock option plan. Sirona is grateful for the continued support of its shareholders, and looks forward to a successful year.
About Sirona Biochem Corp.
Sirona Biochem is an innovative cosmetic ingredient and drug discovery company that utilizes a cutting-edge proprietary platform technology. Their aim is to stabilize carbohydrate molecules, thereby making them more effective and safer for use. By patenting these new compounds, Sirona Biochem is able to maximize its potential revenue.
Sirona’s innovative compounds are licensed to renowned companies worldwide, receiving licensing fees, milestone fees, and ongoing royalty payments in return. Our laboratory, TFChem, based in France, has earned multiple prestigious national awards and European Union and French government grants. We are proud to be at the forefront of scientific progress, helping to shape the future.